Compounds > morphine chloride
Page last updated: 2024-12-11

morphine chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

morphine hydrochloride : The hydrochloride salt of morphine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5464110
CHEMBL ID556578
CHEBI ID55340
SCHEMBL ID40902
MeSH IDM0014065

Synonyms (53)

Synonym
einecs 200-136-2
morphine chlorhydrate
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, hydrochloride (9ci)
morphine chloride
(-)-morphine hydrochloride
ampek
52-26-6
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, hydrochloride, (5-alpha,6-alpha)-
morphine hydrochloride
epimore
morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-, hydrochloride
thebametten
morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, hydrochloride (8ci)
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-, hydrochloride
theba-intran
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol hydrochloride
CHEBI:55340 ,
morphine hcl
morphine-hcl
vendal
morphine hydro chloride
CHEMBL556578
morphinum muriaticum
morphini hydrochloridum
j28ge0rovx ,
unii-j28ge0rovx
morphine hydrochloride [usp:jan]
morphinum muriaticum [hpus]
morphine hydrochloride [mi]
morphine hydrochloride [mart.]
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, hydrochloride (1:1)
morphine hydrochloride [ep monograph]
morphine hydrochloride [who-dd]
morphine hydrochloric acid salt
XCKKIKBIPZJUET-VYKNHSEDSA-N
SCHEMBL40902
morphiniumchloride
7,8-didehydro-4,5-epoxy-17-methyl-(5?,6?)-morphinan-3,6-diol hydrochloride
AKOS024458522
DTXSID10110023
morphin-hcl
opso
Q27124243
(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;hydrochloride
morphinium chloride
(5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol, hydrochloride (1:1)
(+/-)-morphine hydrochloride
DTXSID501045894
morphine hydrochloride (mart.)
morphine hydrochloride (usp:jan)
morphine hydrochloride (ep monograph)
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5alpha,6alpha)-, hydrochloride (1:1)
morphine.hcl
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)IC50 (µMol)0.03400.00030.50267.7625AID62857; AID62858
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03400.00030.39075.4000AID62857; AID62858
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03400.00030.35635.4000AID62857; AID62858
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03400.00030.38715.4000AID62857; AID62858
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03400.00010.54948.4000AID62857; AID62858
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID1132897Agonist activity at opioid receptor in myenteric plexus of guinea pig ileum relative to morphine1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID229910Sodium response ratio is calculated from the IC50 determined in the presence of sodium ion to the IC50 determined in the absence of sodium ion.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Assessment of the in vivo and in vitro opioid activity of bridged hexahydroaporphine and isoquinoline molecules.
AID1148739Analgesic Activity in sc dosed albino dd mouse by tail pressure stimuli method1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
10-Hydroxy-4-methyl-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine derivatives (homobenzomorphans) as analgesics.
AID1216219Plasma concentration at steady state in Sprague-Dawley rat plasma at 1.56 mg/kg/hr bolus infusion for 10 mins followed by 0.20 mg/kg/hr constant infusion for 110 mins by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID112526In vivo analgesic activity in mice after subcutaneous administration by hot plate assay method.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds.
AID1149071Analgesic activity in sc dosed mouse by Eddy hot-plate assay1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Optical resolution of (+/-)-2,5-dimethyl-2'-hydroxy-9alpha- and -9beta-propyl-6,7-benzomorphans and their pharmacological properties.
AID131580Subcutaneous dose inhibiting acetic acid induced writhing 1 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1216209Unbound brain to plasma concentration ratio in premature lambs2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1135381Physical dependence capacity in rhesus monkey assessed as suppression/precipitation of abstinence syndrome at 4 mg/kg1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
B/C-cis- and -trans-1,3,4,9,10,10a-Hexahydro-2H-10,4a-methanoiminoethanophenanthrene (homo- and homoisomorphinan) derivatives as analgesics.
AID780565Displacement of [3H]DPDPE from delta opioid receptor in CD1 mouse brain membranes after 1 hr by liquid scintillation counting2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
N-Alkyl dien- and trienamides from the roots of Otanthus maritimus with binding affinity for opioid and cannabinoid receptors.
AID1133230Analgesic activity in po dosed mouse by phenylquinone writhing method1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 2. Structure-activity relationships of 1-cycloalkyl-4-(1,2-diphenylethyl)piperazines.
AID113075Analgesic activity measured in mice by jump-producing activity (subcutaneous administration).1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and structure-activity relationships of 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives having narcotic agonist and antagonist activity.
AID1216231Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 0.4 ng/ml by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216214Plasma concentration at steady state in Sprague-Dawley rat plasma at 1.56 mg/kg/hr bolus infusion for 10 mins followed by 0.20 mg/kg/hr constant infusion for 110 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID116495Analgesia was determined by writhing test in mice after 10 mg/kg oral administration1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and analgesic properties of some conformationally restricted analogues of profadol.
AID1136973Analgesic activity in sc dosed mouse by hot-plate method1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Azabicycloalkanes as analgetics. 3. Structure-activity relationships of 1-phenyl-6-azabicyclo[3.2.1]octanes and absolute stereochemistry of (+)-1-(3-hydroxyphenyl)-6-methyl-6-azabicyclo[3.2.1]octane and its 7-endo-methyl derivative.
AID131578Subcutaneous dose at which 50% of the mouse start to lick their paws later than 10 s using hot plate assay.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID149037Concentration for 50% inhibition of [3H]naloxone (1 M) binding to opioid receptor in rat brain membrane was determined in the presence of NaCl1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID149036Concentration for 50% inhibition of [3H]naloxone (1 M) binding to opioid receptor in rat brain membrane was determined in the absence of NaCl1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID1132842Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing response at 10 mg/kg, po administered 30 mins prior to acetic acid-challenge relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID1216233Unbound volume of distribution in Sprague-Dawley rat brain interstitial fluid measured per gm of brain at 0.4 to 250 ng/ml, iv by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216213Plasma concentration at steady state in Sprague-Dawley rat plasma at 0.4 mg/kg/hr bolus infusion for 10 mins followed by 0.04 mg/kg/hr constant infusion for 110 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID79531Inhibitory effect on the response of isolated ileum to acetylcholine (anti-ACh activity) in guinea pig was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID1216216Plasma concentration at steady state in Sprague-Dawley rat plasma at 0.0156 mg/kg/hr bolus infusion for 10 mins followed by 0.01056 mg/kg/hr constant infusion for 110 mins by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216215Plasma concentration at steady state in Sprague-Dawley rat plasma at 7.80 mg/kg/hr bolus infusion for 10 mins followed by 0.98 mg/kg/hr constant infusion for 110 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216224Drug recovery in Sprague-Dawley rat blood at 10 ng/ml bolus infusion for 10 mins followed by 10 ng/ml constant infusion for 110 mins2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID185354Dose required to produce 50 percent of maximum possible analgesic effect (MPE) was evaluated by rat paw pressure test (iv)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives.
AID1132900Suppression of abstinence in withdrawn, morphine-dependent rhesus monkey1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID1133058Analgetic activity in sc dosed albino DD mouse by tail pressure stimuli method1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and analgetic activity of some benzomorphan analogues.
AID1132845Analgesic activity in mouse by hot-plate test1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID1135107Displacement of [3H]dihydromorphine from opiate receptor in rat brain homogenates after 10 mins by scintillation counting1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Relationships between opiate receptor binding and analgetic properties of prodine-type compounds.
AID131582Subcutaneous dose inhibiting acetic acid induced writhing 8 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1149072Analgesic activity in sc dosed mouse by Nilsen assay1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Optical resolution of (+/-)-2,5-dimethyl-2'-hydroxy-9alpha- and -9beta-propyl-6,7-benzomorphans and their pharmacological properties.
AID1216217Plasma concentration at steady state in Sprague-Dawley rat plasma at 0.0624 mg/kg/hr bolus infusion for 10 mins followed by 0.0078 mg/kg/hr constant infusion for 110 mins by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1171117Analgesic activity in Swiss mouse assessed as increase in thermal threshold at 8 mg/kg, po by hot plate test2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Pimaradienoic acid inhibits inflammatory pain: inhibition of NF-κB activation and cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID1132893Analgesic activity in sc dosed mouse assessed as inhibition of phenylquinone-induced writhing1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID150266Concentration that produces 50% inhibition of stereospecific [3H]naloxone binding to opioid receptors in rat brain in absence of sodium.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Assessment of the in vivo and in vitro opioid activity of bridged hexahydroaporphine and isoquinoline molecules.
AID131579Subcutaneous dose inhibiting acetic acid induced writhing 0.5 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1136976Acute toxicity in sc dosed mouse1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Azabicycloalkanes as analgetics. 3. Structure-activity relationships of 1-phenyl-6-azabicyclo[3.2.1]octanes and absolute stereochemistry of (+)-1-(3-hydroxyphenyl)-6-methyl-6-azabicyclo[3.2.1]octane and its 7-endo-methyl derivative.
AID1124427Analgesic activity in sc dosed mouse by hot-plate method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 11-substituted tetrahydrocannabinols. Synthesis and comparison with the potent cannabinoid metabolites 11-hydroxytetrahydrocannabinols.
AID1216218Plasma concentration at steady state in Sprague-Dawley rat plasma at 0.4 mg/kg/hr bolus infusion for 10 mins followed by 0.04 mg/kg/hr constant infusion for 110 mins by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216230Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 2 ng/ml by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID780566Displacement of [3H]DAMGO from mu opioid receptor in CD1 mouse brain membranes after 1 hr by liquid scintillation counting2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
N-Alkyl dien- and trienamides from the roots of Otanthus maritimus with binding affinity for opioid and cannabinoid receptors.
AID165657Compound was evaluated in vivo for the respiratory activity in four conscious rabbits. The percent change in respiration rate in comparison to the 10-minute period prior to the injection, dose 0.03 kg/uM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID707122Antihyperalgesic activity against thermal hyperalgesia in Swiss mouse assessed as increase in thermal nociceptive threshold at 8 mg/kg, po after 1.5 to 5.5 hrs by hot plate test2012Journal of natural products, May-25, Volume: 75, Issue:5
Kaurenoic acid from Sphagneticola trilobata Inhibits Inflammatory Pain: effect on cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway.
AID150388Concentration that produces 50% inhibition of stereospecific [3H]naloxone binding to opioid receptors in rat brain in presence of sodium.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Assessment of the in vivo and in vitro opioid activity of bridged hexahydroaporphine and isoquinoline molecules.
AID1132846Antidepressant activity in mouse assessed as reversal of reserpine-induced hypothermia measured as cumulative temperature rise at 30 mg/kg administered 17 hrs post reserpine-challenge1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID1216223Ratio of unbound concentration in brain interstitial fluid to blood in human patient with brain trauma2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID131409Peroral dose inhibiting acetic acid induced writhing 1 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1134658Antinociceptive activity in sc dosed Swiss Webster mouse by tail-flick assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Stereochemical studies on medicinal agents. 23. Synthesis and biological evaluation of 6-amino derivatives of naloxone and naltrexone.
AID112188The ED50 value of compound was measured for 50% inhibition for analgesia in mice by the hotplate method1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Synthesis and analgesic properties of some conformationally restricted analogues of profadol.
AID1135376Analgesic activity in sc dosed mouse by hot plate assay1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
B/C-cis- and -trans-1,3,4,9,10,10a-Hexahydro-2H-10,4a-methanoiminoethanophenanthrene (homo- and homoisomorphinan) derivatives as analgesics.
AID1216228Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 50 ng/ml by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1135110Analgesic activity in sc dosed mouse by hot plate method1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Relationships between opiate receptor binding and analgetic properties of prodine-type compounds.
AID131408Peroral dose at which 50% of the mouse start to lick their paws later than 10 s using hot plate assay.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID79532Inhibitory effect on the response of isolated ileum to transmural electrical stimulation in guinea pig (anti-TMS activity) was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID1132896Toxicity in sc dosed mouse1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID231774Ratio for 50% inhibition of [3H]naloxone (1 M) binding to opioid receptor in rat brain membrane was determined in the absence of NaCl to that of presence of NaCl1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID1216225Drug recovery in Sprague-Dawley rat brain at 10 ng/ml bolus infusion for 10 mins followed by 10 ng/ml constant infusion for 110 mins2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216232Drug uptake in Sprague-Dawley rat brain measured per gm of tissue at 0.4 to 250 ng/ml, iv by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID62858Concentration inhibiting the specific binding of [3H]naloxone by 50% in the presence of NaCl1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1216220Plasma concentration at steady state in Sprague-Dawley rat plasma at 7.80 mg/kg/hr bolus infusion for 10 mins followed by 0.98 mg/kg/hr constant infusion for 110 mins by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1149073Physical dependence capacity in monkey assessed as single dose suppression of morphine withdrawal syndrome at 1.5 to 6 mg/kg1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Optical resolution of (+/-)-2,5-dimethyl-2'-hydroxy-9alpha- and -9beta-propyl-6,7-benzomorphans and their pharmacological properties.
AID1132898Antagonist activity at opioid receptor in myenteric plexus of guinea pig ileum relative to nalorphine1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID1216222Ratio of unbound concentration in brain interstitial fluid to blood in pig2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID131411Peroral dose inhibiting acetic acid induced writhing 8 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1216212Plasma concentration at steady state in Sprague-Dawley rat plasma at 0.0624 mg/kg/hr bolus infusion for 10 mins followed by 0.0078 mg/kg/hr constant infusion for 110 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1132892Analgesic activity in sc dosed mouse by hot plate method1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID1132891Analgesic activity in sc dosed mouse by tail clip method1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID165665Compound was evaluated in vivo for the respiratory activity in four conscious rabbits. The percent change of the respiratory volume in comparison to the 10-minute prior to the injection, dose 0.03 kg/uM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID133063Percent inhibition of the charcoal meal transfer in mice(100 mg/kg).1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Synthesis and spasmolytic activities of 2-(1,2-benzisoxazol-3-yl)-3-[[omega-(dialkylamino)alkoxy]phenyl]acrylonitriles.
AID1147845Analgesic activity in sc dosed mouse by tail-flick test1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties.
AID1216221Ratio of unbound concentration in brain interstitial fluid to blood in rat2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1132895Toxicity in mouse assessed as Straub tail activity1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID130704In vivo inhibition of subcutaneously administered naloxone-elicited opioid type withdrawal jumping (IWJ) after 72 hours in physically dependent male mice (strain Fullinsdorf-Albino SPF), dose 0.03 kg/uM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.
AID1190338Displacement of [3H]DAMGO from mu opioid receptor in CD1 mouse whole brain minus cerebellum membranes by liquid scintillation counting2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Methoxyflavones from Stachys glutinosa with binding affinity to opioid receptors: in silico, in vitro, and in vivo studies.
AID1216227Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 50 ng/ml by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID145934Ability to inhibit the specific binding of [3H]- dihydromorphine to opiate receptors in rat brain membrane preparation by 50%1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds.
AID62857Concentration inhibiting the specific binding of [3H]naloxone by 50% in the absence of NaCl1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID1133234Analgesic activity in sc dosed rat by Haffner method1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 2. Structure-activity relationships of 1-cycloalkyl-4-(1,2-diphenylethyl)piperazines.
AID1136970Analgesic activity in sc dosed mouse assessed as inhibition of AcOH-induced writhing1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Azabicycloalkanes as analgetics. 3. Structure-activity relationships of 1-phenyl-6-azabicyclo[3.2.1]octanes and absolute stereochemistry of (+)-1-(3-hydroxyphenyl)-6-methyl-6-azabicyclo[3.2.1]octane and its 7-endo-methyl derivative.
AID1216226Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 10 ng/ml by accelerator mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1216234Ratio of unbound concentration in brain interstitial fluid to blood in human patient with brain trauma co-treated with probenecid2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID1190342Analgesic activity in acute pain CD1 mouse model assessed as withdrawal latency time from radiant heat source at 5 mg/kg, ip after 60 mins by tail-flick assay relative to control2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Methoxyflavones from Stachys glutinosa with binding affinity to opioid receptors: in silico, in vitro, and in vivo studies.
AID1147842Analgesic activity in sc dosed mouse by hot plate test1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties.
AID1190339Displacement of [3H]DPDPE from delta opioid receptor in CD1 mouse whole brain minus cerebellum membranes by liquid scintillation counting2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Methoxyflavones from Stachys glutinosa with binding affinity to opioid receptors: in silico, in vitro, and in vivo studies.
AID1132905Ratio of LD50 in sc dosed mouse to ED50 in sc dosed mouse by writhing test1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Diastereoisomeric N-tetrahydrofurfurylnoroxymorphones with opioid agonist--antagonist properties.
AID113088Analgesic activity measured in mice by the tail-flick test (subcutaneous administration)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and structure-activity relationships of 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives having narcotic agonist and antagonist activity.
AID1133229Analgesic activity in sc dosed mouse by D'Amour-Smith method1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities. 2. Structure-activity relationships of 1-cycloalkyl-4-(1,2-diphenylethyl)piperazines.
AID1216229Ratio of unbound concentration in brain to blood in Sprague-Dawley rat measured at steady state plasma concentration of 250 ng/ml by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
AID131410Peroral dose inhibiting acetic acid induced writhing 24 hr after administration in 50% of the rats.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
AID113087Analgesic activity measured in mice by the phenylquinone writhing test (subcutaneous administration).1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Synthesis and structure-activity relationships of 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives having narcotic agonist and antagonist activity.
AID1216210Unbound brain to plasma concentration ratio in adult sheep2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (72.00)18.7374
1990's2 (8.00)18.2507
2000's0 (0.00)29.6817
2010's5 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.51 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9610organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		1.9710aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
imipramine
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.		1.9510dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.4920aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
meperidine hydrochloride
pethidine hydrochloride : The hydrochloride salt of pethidine. An analgesic used for the treatment of postoperative and labour pain.		1.9510hydrochlorideantispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		1.9710aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
papaverine hydrochloride
[no description available]		1.9610
dronabinol
Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.		1.9510benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
butaclamol
[no description available]		1.9610amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist
spiradoline
spiradoline: RN given refers to (5alpha,7alpha,8beta)-(+-)-isomer; structure given in first source		1.9710
tangeretin
tangeretin: structure given in first source; from citrus plants; inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. tangeretin : A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8.. pentamethoxyflavone : A methoxyflavone that is flavone substituted by a five methoxy groups.		2.1110pentamethoxyflavoneantineoplastic agent;
plant metabolite
kaurenoic acid
[no description available]		2.0710ent-kaurane diterpenoidanti-HIV-1 agent;
antineoplastic agent;
plant metabolite
xanthomicrol
xanthomicrol: structure in first source. xanthomicrol : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 8 and hydroxy groups at positions 5 and 4'.		2.1110dihydroxyflavone;
trimethoxyflavone		antineoplastic agent;
plant metabolite
gardenin b
gardenin B: has antineoplastic activity; structure in first source. gardenin B : A tetramethoxyflavone that is tangeretin in which the methoxy group at position 5 has been replaced by a hydroxy group.		2.1110monohydroxyflavone;
tetramethoxyflavone		plant metabolite
sideritoflavone
sideritoflavone: methoxyflavone from Stachys glutinosa with binding affinity to opioid receptors; structure in first source		2.1110ether;
flavonoids
4',5-dihydroxy-3',6,7,8-tetramethoxyflavone
[no description available]		2.1110
delta-8-tetrahydrocannabinol
[no description available]		1.95101-benzopyran
11-hydroxy-delta(9)-tetrahydrocannabinol
11-hydroxy-delta(9)-tetrahydrocannabinol: metabolite of marijuana; structure; RN given refers to cpd without isomeric designation. 11-hydroxy-Delta(9)-tetrahydrocannabinol : A phytocannabinoid that is Delta(9)-tetrahydrocannabinol in which the methyl group at C-11 has been hydroxylated . Major metabolite of Delta(9)-tetrahydrocannabinol.		1.9510phytocannabinoidhuman xenobiotic metabolite
eupatilin
eupatilin: isolated from Artemisia argyi. eupatilin : A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities.		2.1110dihydroxyflavone;
trimethoxyflavone		anti-inflammatory agent;
anti-ulcer drug;
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite
codeine
[no description available]		1.9510morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		1.9610morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
oxycodone
Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.		2.3920organic heteropentacyclic compound;
semisynthetic derivative		antitussive;
mu-opioid receptor agonist;
opioid analgesic
oxymorphone
Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)		1.9610morphinane alkaloid
codeine phosphate
[no description available]		2.6430
naloxone hydrochloride
naloxone hydrochloride : A hydrochloride resulting from the formal reaction of equimolar amounts of naloxone and hydrogen chloride. A specific opioid antagonist, it is used to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		2.6430hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
nalorphine hydrochloride
[no description available]		2.6430
naltrexone hydrochloride
naltrexone hydrochloride : A hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. it is a mu-opioid receptor antagonist that is used to treat alcohol dependence.		1.9510hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
(2E,4E)-N-isobutyl-2,4-dodecadienamide
[no description available]		2.0810fatty amidemetabolite
butylscopolammonium bromide
Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.		1.9610
pimaric acid
[no description available]		2.110
atropine sulfate
[no description available]		1.9610
morphine sulfate
[no description available]		1.9710alkaloid sulfate salt
ConditionIndicatedRelationship StrengthStudiesTrials
Chemical Dependence
[description not available]		02.3520
Drug Withdrawal Symptoms
[description not available]		02.3620
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.3620
Substance-Related Disorders
Disorders related to substance use or abuse.		02.3520
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		02.3620
Abnormal Deep Tendon Reflex
[description not available]		01.9510
Reflex, Abnormal
An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.		01.9510
Hypothermia, Accidental
[description not available]		01.9510
Muscle Spasm
[description not available]		01.9510
Hypothermia
Lower than normal body temperature, especially in warm-blooded animals.		01.9510
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		01.9510
Morphine Abuse
[description not available]		01.9510
Morphine Dependence
Strong dependence, both physiological and emotional, upon morphine.		01.9510
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710
Addiction, Opioid
[description not available]		01.9710
Opioid-Related Disorders
Disorders related to or resulting from abuse or misuse of OPIOIDS.		13.9710
Innate Inflammatory Response
[description not available]		02.0710
Ache
[description not available]		02.4920
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0710
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		14.4920
Anasarca
[description not available]		02.110
Allodynia
[description not available]		02.110
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.110